Relay Therapeutics, Inc. RLAY EBITDA margin

EBITDA margin at other companies

SchrodingerSDGR

-57%-12.2pp

Recursion Pharmaceuticals, Inc.RXRX

-848.9%-51.7pp

Revolution Medicines, Inc.RVMD

-87,211.9%-88,649pp

Ligand PharmaceuticalsLGND

43.9%+43.6pp

ImmunomeIMNM

-5,886.7%-11,897pp

Zevra Therapeutics, Inc.ZVRA

65.5%+37.8pp

FAQ

What is Relay Therapeutics, Inc.'s EBITDA margin?

Relay Therapeutics, Inc. (RLAY) reported EBITDA margin of -2,978% in Q2 2026.

How has Relay Therapeutics, Inc.'s EBITDA margin changed year-over-year?

Relay Therapeutics, Inc.'s EBITDA margin increased by 26.4% year-over-year, from -4,046.8% to -2,978%.

What is the long-term trend for Relay Therapeutics, Inc.'s EBITDA margin?

Over 4 years (2021 to 2025), Relay Therapeutics, Inc.'s EBITDA margin has grown at a -36.4% compound annual growth rate (CAGR), from -11,910.6% to -1,948.3%.

What does EBITDA margin mean?

EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.